What is nmCRPC?
When prostate cancer progresses
When prostate cancer progresses after initial treatment (i.e. surgery or radiation), men may receive medical or surgical treatments that lower testosterone, also referred to as androgen deprivation therapy (ADT).
ADT includes treatments to suppress or block the production or action of male hormones called androgens, of which testosterone is the primary androgen. While ADT is often effective, in certain men prostate cancer adapts and can progress.
Prostate-specific antigen (PSA) is one of the ways your doctor may monitor your prostate cancer. Often, PSA levels rise, which could be one of the indicators that the cancer may be progressing. Bone and other types of scans are used to detect whether the cancer has spread to different parts of the body.
Prostate cancer that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone is called non-metastatic castration-resistant prostate cancer or nmCRPC.